Dec 07

Finding Common-sense Methods For Qualification For Obstetrics

has been honored by industry peers as the 2016 Ag Retailer of the Year throughout the United States. The award honors agricultural retailers who represent the best in innovative business practices, community and industry leadership, environmental stewardship, reliability, technology utilization, customer service and effective employee development. Professional boxer and WBC Continental Americas super lightweight champion Jose Ramirez received The CrisCom Companys Leader For America award. This award is the companys highest honor recognizing those extraordinary leaders who have made a tremendous impact benefiting the nation in a positive way. The Fresno Area Hispanic Foundation honored longtime community partner Bank of America for economic development at the State of the City. For over a decade, Bank of America has supported the foundations programs and services that provide technical assistance to startup and existing businesses, including the Downtown Business Hub incubator, established in 2011 as the first bilingual business incubator in the western United States. Donations For the 10th consecutive year, Fresno 7-Eleven franchisee Serge Haitayan will donate more than 800 coats to local students just in time for cooler weather. a simple breakdown of level-headed interview job video tacticsSince 2007, Haitayan has donated more than 5,250 coats to students and families of Clovis and Fresno Unified school districts. Coats this year will be donated to students at Molly S. Bakman, Turner, Fancher Creek and Temperance Kutner elementary schools. The Rotary Club of Fresno awarded $1,500 to the Deaf and Hard of Hearing Center Inc.

For the original version including any supplementary images or video, visit http://www.fresnobee.com/news/business/article118276033.html

Goldman, Sachs & Co., BofA Merrill Lynch and Cowen and Company are acting as joint book-running managers of the proposed offering. Wells Fargo Securities and Wedbush PacGrow are acting as co-managers. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering. The shares are being offered by bluebird bio pursuant to an automatically effective shelf registration statement that was previously filed with the Securities and Exchange Commission (SEC). A preliminary prospectus supplement relating to and describing the terms of the offering will be filed with the SEC and will be available on the SECs website at www.sec.gov . When available, copies of the preliminary prospectus supplement and the accompanying prospectus relating to these securities may also be obtained by contacting one of the following: Goldman, Sachs & Co., Attn: Prospectus Department, 200 West Street, New York, NY 10282, telephone: (212) 902-1171, facsimile: (212) 902-9316, email: prospectus-ny@ny.email.gs.com ; BofA Merrill Lynch, NC1-004-03-43, 200 North College Street, 3rd floor, Charlotte, NC 28255-0001, Attn: Prospectus Department, email: dg.prospectus_requests@baml.com ; or Cowen and Company, LLC, c/o Broadridge Financial Services, 1155 Long Island Avenue, Edgewood, NY, 11717, Attn: Prospectus Department, by telephone at (631) 274-2806 or by fax at (631) 254-7140. Continue ReadingThe final terms of the offering will be disclosed in a final prospectus supplement to be filed with the SEC. This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of, these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of such state or jurisdiction. About bluebird bio, Inc. With its lentiviral-based gene therapy and gene editing capabilities, bluebird bio has built an integrated product platform with broad potential application to severe genetic diseases and cancer. bluebird bios gene therapy clinical programs include its Lenti-D product candidate, currently in a Phase 2/3 study, called the Starbeam Study, for the treatment of cerebral adrenoleukodystrophy, and its LentiGlobin BB305 product candidate, currently in four clinical studies for the treatment of transfusion-dependent beta-thalassemia and severe sickle cell disease.

For the original version including any supplementary images or video, visit http://finance.yahoo.com/news/bluebird-bio-announces-proposed-public-211900417.html



You may also be interested to read

Leave a Reply

Your email address will not be published. Required fields are marked *

You may use these HTML tags and attributes: <a href="" title=""> <abbr title=""> <acronym title=""> <b> <blockquote cite=""> <cite> <code> <del datetime=""> <em> <i> <q cite=""> <strike> <strong>